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Diverse role of survival motor neuron protein
Abstract
The multifunctional Survival Motor Neuron (SMN) protein is required for the survival of all organisms of the
animal kingdom. SMN impacts various aspects of RNA metabolism through the formation and/or interaction
with ribonucleoprotein (RNP) complexes. SMN regulates biogenesis of small nuclear RNPs, small nucleolar
RNPs, small Cajal body-associated RNPs, signal recognition particles and telomerase. SMN also plays an
important role in DNA repair, transcription, pre-mRNA splicing, histone mRNA processing, translation,
selenoprotein synthesis, macromolecular trafficking, stress granule formation, cell signaling and cytoskeleton
maintenance. The tissue-specific requirement of SMN is dictated by the variety and the abundance of its
interacting partners. Reduced expression of SMN causes spinal muscular atrophy (SMA), a leading genetic
cause of infant mortality. SMA displays a broad spectrum ranging from embryonic lethality to an adult onset.
Aberrant expression and/or localization of SMN has also been associated with male infertility, inclusion body
myositis, amyotrophic lateral sclerosis and osteoarthritis. This review provides a summary of various SMN
functions with implications to a better understanding of SMA and other pathological conditions.
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Abstract
The multifunctional Survival Motor Neuron (SMN) protein is required for the survival of all 
organisms of the animal kingdom. SMN impacts various aspects of RNA metabolism through the 
formation and/or interaction with ribonucleoprotein (RNP) complexes. SMN regulates biogenesis 
of small nuclear RNPs, small nucleolar RNPs, small Cajal body-associated RNPs, signal 
recognition particles and telomerase. SMN also plays an important role in DNA repair, 
transcription, pre-mRNA splicing, histone mRNA processing, translation, selenoprotein synthesis, 
macromolecular trafficking, stress granule formation, cell signaling and cytoskeleton maintenance. 
The tissue-specific requirement of SMN is dictated by the variety and the abundance of its 
interacting partners. Reduced expression of SMN causes spinal muscular atrophy (SMA), a 
leading genetic cause of infant mortality. SMA displays a broad spectrum ranging from embryonic 
lethality to an adult onset. Aberrant expression and/or localization of SMN has also been 
associated with male infertility, inclusion body myositis, amyotrophic lateral sclerosis and 
osteoarthritis. This review provides a summary of various SMN functions with implications to a 
better understanding of SMA and other pathological conditions.
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1. Introduction
Survival Motor Neuron (SMN) is a multifunctional protein expressed in all cell types of the 
animal kingdom. The importance of SMN in humans was first realized when deletions or 
mutations in the SMN1 gene were found to cause Spinal Muscular Atrophy (SMA), the 
leading genetic disease of children and infants [1–4]. Owing to duplication and inversion, 
humans carry an additional centromeric copy of the SMN gene, SMN2 [2]. SMN1 codes for 
SMN, while SMN2 primarily produces the truncated protein isoform (SMNΔ7) due to 
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predominant skipping of exon 7. Thus, SMN2 fails to fully compensate for the loss of 
SMN1 [5,6]. Although SMNΔ7 is less stable and only partially functional [7–9], 
overexpression of this isoform reduces the disease severity in a mouse model of SMA [10]. 
Mice carry a single Smn gene. Deletion of Smn gene is embryonic lethal [11]; however, 
introduction of human SMN2 rescues the embryonic lethality [12]. The presence of a single 
copy of SMN2 in mice lacking Smn gene produces a phenotype resembling that of severe 
SMA [12]. A higher copy number of SMN2 is associated with reduced disease severity 
[13,14]. Several protein factors, including Plastin3, NAIP, H4N4, IGF1, ZPR1 and UBA1, 
have been suggested as modifiers of SMA severity [15–19]. However, none of these factors 
have the ability to fully compensate for the loss of SMN functions.
Human SMN contains 294 amino acids and harbors multiple domains, including N-terminal 
Gemin2- and nucleic acid-binding domains, a central Tudor domain and C-terminal proline-
rich and YG domains (Fig. 1). Mutations in all domains have been linked to SMA [28], 
suggesting that the overall structure of the protein is critical for its functions in humans. 
SMN localizes to both nuclear and cytosolic compartments. In particular, SMN plays an 
essential role in the formation of nuclear gems that share several components with the Cajal 
(coiled) bodies (CBs) [29–31]. CBs are dynamic nuclear structures that serve as the 
storehouse and/or maturation site for the ribonucleoprotein (RNP) complexes, including 
small nuclear RNPs (snRNPs), small nucleolar RNPs (snoRNPs), small CB-specific RNPs 
(scaRNPs) and telomerase RNP complexes [32]. SMN interacts with coilin, a signature 
protein of CBs [33]. The interaction between SMN and coilin is facilitated by WRAP53, a 
WD40 domain-containing protein, which is also essential for the localization of the SMN 
complex to CBs [34]. The relative abundance of SMN in various subcellular compartments 
is dependent upon the cell type [35]. Within the cytosol, SMN localizes to sarcomeric Z-
discs, microtubules, the Golgi network and cytosolic stress granules (SGs) [36–46].
Alternative splicing of SMN1 and SMN2 generates several transcripts under normal and 
oxidative-stress conditions [47–50]. One of the SMN isoforms is produced by retention of 
intron 3. It codes for axonal-SMN (a-SMN) that plays a developmental role in mammalian 
brain [47]. a-SMN promotes axon growth, stimulates cell motility and regulates expression 
of chemokines (CCL2, CCL7) and insulin-like growth factor-1 [51]. The a-SMN transcripts 
are generally not detected in adult tissues likely due to their degradation by the nonsense-
mediated decay (NMD) pathway. Another SMN protein isoform, SMN6B, is generated by 
exonization of an Alu-like sequence located within intron 6 (Fig. 1) [50]. While the SMN6B 
splice isoform is subject to NMD, SMN6B protein was shown to be more stable than 
SMNΔ7 [50]. The functions of SMN6B as well as SMN isoforms generated by skipping of 
exons 5 and/or 3 remain unknown.
In addition to SMA, the involvement of SMN has also been shown in other pathological 
conditions. For instance, the role of SMN has been implicated in inclusion body myositis, 
amyotrophic lateral sclerosis (ALS) and osteoarthritis [52–54]. Supporting a role of SMN in 
mammalian testicular development and male fertility, its levels in testis are very high 
compared to other organs and tissues due in part to the predominant inclusion of exon 7 
during SMN2 pre-mRNA splicing [55,56]. Consistently, under the condition of decreased 
SMN levels, male mice display defective testicular development, impaired spermatogenesis 
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and reduced fertility [57]. Interestingly, an aberrant high SMN expression was recorded in 
osteoarthritis cartilage compared to the normal cartilage [54]. However, it remains to be seen 
if the high SMN expression in osteoarthritis cartilage is a cause or effect of osteoarthritis.
SMA happens to be a unique genetic disease, since SMN2 copy of the gene is almost 
universally present in patients. Hence, SMN2 is considered to be the most promising 
therapeutic target. Currently, compounds that enhance SMN2 transcription, correct SMN2 
exon 7 splicing, increase stability of SMN and/or SMNΔ7 proteins and allow stop codon 
read through of SMN2Δ7 transcripts, are being considered as potential candidates for SMA 
therapy [58]. An antisense-based drug targeting intronic splicing silencer N1 (ISS-N1) we 
discovered in 2006 has just completed phase 3 clinical trials and is likely to become the first 
FDA-approved drug for SMA [28,59–62]. Many recent reviews describe the role of SMN in 
neurodegeneration and the progress toward SMA therapy [63–67]. Similarly, several reports 
summarize the current knowledge of cis-elements and transacting factors that are involved in 
regulation of SMN transcription and splicing [68–71]. The purpose of this review is to focus 
on the diverse nature of SMN functions and discuss how reduced levels of SMN might 
differentially affect a variety of human tissues. Based on the presence of sequence/structural 
motifs and the nature of SMN interactions, it is obvious that SMN functions have continued 
to evolve and diversify. We will describe how lessons learnt from the employment of various 
model systems and profiling studies are improving our understanding of SMN functions. 
Given a broad spectrum of SMA phenotype and related diseases, we are tempted to 
speculate that SMN has multiple housekeeping functions that are differently regulated in 
various cell types.
2. Domain Organization
Alignment of SMN amino acid sequences across several species shows its remarkable 
conservation in higher vertebrates (Fig. 2). Three stretches of more than fifty conserved 
residues of vertebrate SMN are located at the N-terminus, central region and C-terminus 
(Fig. 2). All of these regions are known to have interacting partners (Fig. 1). The nucleic 
acid-binding domain coded by exons 2A and 2B is conserved and overlaps with the binding 
site of the SMN-Interacting Protein 1 (SIP1), also known as Gemin2 [72–74]. The core 
complex formed by SMN-Gemin2 appears to be central to most functions of SMN in 
vertebrates, including snRNP assembly, DNA recombination, signal recognition particle 
biogenesis and translation regulation [20,75–77]. The domain encoded by exon 2 also 
interacts with p53, a tumor suppressor protein and transcription regulator [78]. Exon 3 of 
SMN codes for a Tudor domain that is involved in interactions with proteins carrying 
RGG/RG motifs, which are symmetrically dimethylated [79–81]. The examples of these 
proteins include but are not limited to GAR1, Fibrillarin, hnRNP Q, hnRNP R, hnRNP U, 
Ewing’s Sarcoma Protein (EWS), Fragile X Mental Retardation Protein (FMRP), Fused in 
Sarcoma (FUS), Sm proteins, Histone 3 and the carboxy terminal domain (CTD) of RNA 
Polymerase II (pol II) [29,82–92]. Downstream of the Tudor domain, SMN contains a 
proline-rich sequence (Fig. 1). This sequence interacts with Profilins, a family of small 
proteins that control the actin dynamics in the cell [93]. The last sixteen amino acids (coded 
by exon 7) together with the upstream YG box (coded by exon 6) facilitate self-
oligomerization that appears to be critical for stability and subcellular localization of SMN 
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[9,94,95]. The C-terminal sequences of SMN, including YG box, are also involved in the 
interaction with Gemin3 (a dead-box helicase), ZPR1 (a zinc-finger protein) and SIN3A (a 
transcription co-repressor) [96–98]. The loss of amino acids coded by exon 7 has been 
shown to abrogate SMN interaction with Trimethylguanosine Synthase 1 (TGS1), which 
catalyzes the formation of 2,2,7-trimethylguanosine (TMG) cap structure at the 5´-end of the 
snRNAs, snoRNAs and a subpopulation of mRNAs [99,100]. The QNQKE motif present 
within sequences coded by exon 7 serves as a nuclear export signal [35]. Zebrafish Smn with 
mutations in QNQKE motif retains the snRNP assembly function but fails to rescue motor 
axon defects [101]. Skipping of exon 7 adds a four-amino acid motif, EMLA, coded by exon 
8. EMLA serves as a degradation signal for SMNΔ7, which explains its decreased stability 
[9]. Compounds that allow read through of the stop codon in exon 8 and cause a few amino 
acids being added downstream of EMLA, increase the protein stability and show therapeutic 
efficacy in mouse models of SMA [102,103].
The C-terminal YG box of SMN is the most conserved motif from yeast to humans (Fig. 2). 
The YG box of yeast SMN is needed for cell viability but is dispensable for interactions with 
Sm proteins and self-oligomerization [104]. Interestingly, the genome of Arabidopsis 
thaliana lacks a true ortholog of SMN [105]. These observations support a point of view that 
in lower eukaryotes and plants other proteins perform SMN-like functions. Despite 
conservation of several SMN motifs among vertebrates, noticeable differences do exist at the 
N- and C-termini (Fig. 2). In particular, the N-terminus of SMN appears to be specific to 
mammals; it harbors binding sites for several critical interacting partners (Fig. 1). 
Consistently, SMNΔN27, a SMN mutant lacking 27 N-terminal amino acids, displays a 
dominant negative effect on various SMN functions, including splicing, snRNP 
reorganization, telomerase activity and hyper methylation by TGS1 activity [99,106,107]. 
The absence of the mammalian-specific N-terminal sequences in lower vertebrates suggests 
that during evolution mammalian SMN has undergone drastic changes in its structure and 
functions. Additionally, in comparison to mammalian SMN, the polyproline region is 
substantially shorter in non-mammal vertebrates; it is completely absent in Drosophila 
melanogaster and Caenorhabditis elegans (Fig. 2). There appears to be further addition to the 
structure/function of primate SMN due in part to the inclusion of a coding exon derived from 
an Alu element [50].
3. Role of SMN in RNA metabolism
SMN controls various aspects of the RNA metabolism, including but not limited to 
transcription [90], pre-mRNA splicing [106], snRNP assembly [20,72,108–115], the 3′ end 
of histone mRNA processing [116,117], snoRNP assembly [82,118,119], telomerase activity 
[119], SG formation [120], translation [121,122], signal recognition particle (SRP) 
biogenesis [123] and mRNA trafficking [124–130] (Fig. 3). Here we provide a brief 
description of the RNA metabolism pathways that are impacted by the low SMN levels.
3.1. Spliceosomal snRNP assembly
Spliceosomal snRNP assembly is the most studied function of SMN thanks to the pioneering 
work from the Dreyfuss laboratory [20,72,108–112]. The action of SMN in snRNP assembly 
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is executed by a large SMN complex comprised of SMN, Gemin proteins (Gemins2–8) and 
Unrip [113–115]. The SMN complex is quite stable, since most of its components remain 
tightly associated even at very high salt concentration (500 nM NaCl) [131]. A spliceosomal 
snRNP is comprised of a snRNA and a heptameric ring of Sm proteins (B/B′, D1, D2, D3, 
E, F, and G) [132]. The function of the SMN complex in ATP-dependent snRNP assembly 
has been demonstrated in vitro [109]. The in vivo process of snRNP biogenesis involves 
multiple distinct steps in the nucleus and cytosol. In the nucleus, a snRNA is transcribed by 
pol II and the newly synthesized snRNA undergoes co-transcriptional processing in which a 
7-methyl guanosine cap (m7G-cap) is added to the 5′ end and the 3′ end is cleaved, 
generating a pre-snRNA [132]. Then a multiprotein export complex comprised of Cap-
Binding Proteins (CBP20 and CBP80), Phosphorylated Adaptor for RNA Export (PHAX), 
Exportin 1 (Xpo1) and RanGTP is assembled on this pre-snRNA to export it to the cytosol 
[115]. Additional factors, including ARS2, p54nrb/NonO and PSF also participate in this 
process [133,134].
Once in the cytosol, the export complex is disassembled and the pre-snRNA undergoes 
further processing by SMN complex, such as loading of the heptameric Sm ring to the pre-
snRNA. Several steps ensure the specificity of the process. For example, the Protein 
Arginine Methyltransferase 5 (PRMT5) complex performs symmetrical dimethylation of a 
subset of Sm proteins, which leads to their tighter interactions with SMN [115]. Further, 
Gemin5 of SMN complex recognizes specific sites on the pre-snRNA for loading of the 
heptameric Sm ring [110]. Recently it has been shown that U1-70K, a component of U1 
snRNP, can substitute the functions of Gemin5 in snRNP assembly [112]. After loading of 
the Sm ring, the pre-snRNA is subjected to hypermethylation of its m7G-cap by TGS1 to 
acquire the TMG cap structure [135]. At this stage, the pre-snRNA also undergoes the 3′ 
end trimming [132]. A direct interaction between SMN and TGS1 appears to be essential for 
the formation of the TMG cap structure on pre-snRNAs [99,136]. Still bound to SMN 
complex, the newly processed snRNP is imported back into the nucleus. The TMG cap and 
the Sm core serve as the nuclear localization signal [137–139]. A direct interaction between 
SMN and Importin-β facilitated by WRAP53 has also been implicated in the nuclear import 
of snRNPs [34,95]. Once in the nucleus, the snRNA goes through final maturation in CBs. 
In particular, a handful of nucleotides of snRNAs are pseudouridylated or 2′-O-methylated. 
Interactions between SMN and WRAP53 appear to play an important role in the targeting of 
snRNPs as well as other RNP complexes, such as snoRNPs and telomerase, to CBs [140].
Consistent with the critical role of SMN in snRNP assembly, SMN deficiency causes 
widespread defects in splicing [141–145]. It has been argued that the splicing of minor 
introns in particular is affected in SMA [146]. There is evidence to suggest that some of the 
effects on alternative splicing are indirect, since levels of factors that are involved in splicing 
could also be affected by downregulation of SMN [122]. Overall, the mechanism by which 
SMN deficiency triggers aberrant splicing of specific introns remains to be understood.
3.2. Biogenesis of snoRNPs
snoRNPs belong to a class of RNP complexes that perform posttranscriptional modifications 
of non-coding RNAs, such as ribosomal RNAs (rRNAs) and snRNAs [147]. A typical 
Singh et al. Page 5
Biochim Biophys Acta. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
snoRNP encompasses a small guide RNA (snoRNA), which defines the site of 
posttranscriptional modifications [148], and specific protein factors. Based on the sequence 
and structural motifs, snoRNAs fall into two broad categories, i.e. H/ACA box and C/D box. 
While the H/ACA box snoRNAs guide pseudouridylation, C/D box snoRNAs guide 2′-O-
methylation. A recent review describes various types of snoRNAs and their potential targets 
[149]. Both types of snoRNAs are defined by specific secondary structures. In the case of 
the H/ACA box snoRNAs, two hairpin structures are joined by a single-stranded region 
carrying the H box (ANANNA, where N = G, U, C, A) and the 3′-end region carrying the 
ACA box (AYA, where Y = C or U) motifs. The 5′-end of the C/D box snoRNA contains the 
C box motif (RUGAUGA, where R is purine), whereas, the D box motif (CUGA) is located 
near the 3′-end. The secondary structure of a snoRNA brings C and D box motifs in close 
proximity due to a stem formed by the base pairing of the 5′-end sequences with the 3′-end 
sequences [149]. The defined secondary structures of snoRNAs are necessary for the 
interaction with the target RNAs as well as with protein components of snoRNPs.
Different sets of core proteins and additional auxiliary factors interact with different classes 
of snoRNAs. The core protein components of H/ACA box snoRNAs include Dyskerin, 
GAR1, NHP2 and NOP10. Dyskerin carries the essential catalytic function of 
pseudouridylation performed by H/ACA box snoRNPs. The core protein components of C/D 
box snoRNP include 15.5K, NOP56, NOP58 and fibrillarin [148]. Fibrillarin carries the 
essential methyl transferase activity of C/D box snoRNPs [147]. Supporting its involvement 
in snoRNP biogenesis and/or function, SMN was shown to interact with GAR1 and 
Fibrillarin [82,118]. Consistent with these findings, SMN and Fibrillarin co-localize within 
dense fibrillary components of nucleoli of HeLa cells [82]. As per several other studies, a 
substantially greater abundance of SMN is observed in nucleoli of primary tissues than of 
cultured cells [150–152]. Interestingly, SMN also interacts with NAF1, a non-snoRNP 
protein responsible for the assembly of the H/ACA box class of snoRNPs [119]. However, it 
remains to be seen if the assembly of the H/ACA box snoRNPs is differentially impacted by 
the low levels of SMN.
A subset of snoRNPs referred to as scaRNPs (small CB-specific RNPs) localizes to CBs; 
they are mainly involved in snRNA modifications [153]. A CAB box (UGAG) motif within 
the hairpin loop of H/ACA box of scaRNAs serves as the guide sequence for the localization 
of scaRNPs to CBs [154]. Experiments in D. melanogaster have shown that WDR79, a 
homolog of human WRAP53, interacts with the CAB box and transports CAB box-
containing scaRNPs to CBs [155]. In case of the C/D box scaRNAs, a long UG dinucleotide 
repeat serves as the CB-targeting sequence [156]. However, factors involved in the 
transporting of C/D box scaRNAs to CBs have not yet been identified. SMA patient cells 
show disruption of CB formation as well as decreased localization of snoRNP/scaRNP 
chaperone Nopp140 to CBs [34,157]. Depletion of SMN leads to similar consequences [34]. 
It is likely that the interaction of SMN with the components of scaRNPs coupled with the 
interaction of SMN with WRAP53 and Coilin drives localization of scaRNPs to CBs.
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3.3. Biogenesis of telomerase
Telomerase is a multi-component RNP complex that catalyzes replication of chromosomal 
ends. Subunits of a human telomerase include a RNA component (TERC), a reverse 
transcriptase (TERT) and proteins associated with H/ACA box scaRNAs [158]. Human 
TERC is transcribed by pol II and accumulates in cells as a 451 nt-long RNA after being 
processed from a longer transcript [159]. The secondary structure of TERC provides the 
context for RNA-protein interactions as well as for defining the boundaries of the template 
for TERT [158]. In particular, the 5′-end of TERC folds into a pseudoknot structure and 
encompasses the template and the binding site of TERT. A conserved region (CR4-CR5) in 
the middle of TERC also interacts with TERT. The 3′-end of TERC folds into an H/ACA 
box scaRNA-like structure and interacts with NHP2, NOP10, GAR1, Dyskerin and 
WRAP53/TCAB1 [158]. The involvement of SMN in telomerase-associated functions has 
been proposed based on the findings that SMN interacts with multiple components of 
telomerase, including GAR1, TERT, Dyskerin and WRAP53 [82,107,119]. One of the likely 
consequences of the above-mentioned interactions of SMN is the transport of telomerase to 
CBs. Considering CBs associate with telomeres during S-phase [160], SMN is likely to have 
an influence on the maintenance of the chromosome telomeres. SMN may also facilitate the 
de novo assembly of telomerase, since it also interacts with NAF1, a factor responsible for 
the de novo assembly of the H/ACA box class of snoRNPs [119]. SMNΔN27, the dominant 
negative isoform of SMN, inhibits the telomerase reaction in vitro [107], suggesting that 
SMN may have a direct effect on the catalytic function of telomerase.
3.4. The 3′ end processing of histone mRNAs
Histone mRNAs require special 3′ end processing, since they are not polyadenylated, and 
U7 snRNP plays an essential role in this process [161]. The 3′ end of histone mRNAs 
contains a stem-loop structure followed by a cleavage site. U7 snRNP is recruited 
downstream of the cleavage site and in conjunction with a stem-loop-binding protein and 
other factors, facilitates the cleavage at the 3′ end of histone mRNAs [161]. Except for a 
few differences, the overall architecture of U7 snRNP resembles those of spliceosomal 
snRNPs. Instead of SmD1 and SmD2 found in spliceosomal snRNPs, the heptameric ring of 
U7 snRNP harbors Sm-like proteins Lsm10 and Lsm11 [116,162]. While the role of the 
SMN complex in U7 snRNP assembly is similar to that of spliceosomal snRNP assembly, 
the composition of the SMN complex involved in the U7 snRNP biogenesis is proposed to 
be distinct [116,162]. Consistent with the critical role of SMN in U7 snRNP assembly and 
histone metabolism, SMN deficiency causes accumulation of U7 snRNA and the defective 
processing of the 3′ end of histone mRNAs [117].
3.5. Pre-mRNA splicing
Pre-mRNA splicing is an essential process by which spliceosome removes introns in 
eukaryotes. In addition to the core components of spliceosome, several auxiliary factors are 
also involved in pre-mRNA splicing (see refs. in 48). Independent of its role in snRNP 
biogenesis, there is evidence to support the role of SMN as an auxiliary factor in pre-mRNA 
splicing. For instance, an early in vitro study employing chicken δ-crystallin pre-mRNA 
showed suppression of a splicing reaction when nuclear extract was pre-incubated with a 
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SMNΔN27 [106]. This suppression was not observed when pre-incubation was performed 
with SMN, suggesting that the N-terminal sequences of SMN are critical for the assembly of 
the spliceosome [106]. A splicing reaction involves formation of an early commitment 
complex or E complex that brings the 5′- and 3′-splice sites in close proximity. 
Composition of the E complex as well as subsequent steps might vary depending on the 
sequence of the pre-mRNA and the cell type. A recent study analyzed the composition of the 
E complex assembled on MINX, an adenovirus derived sequence, and identified several 
components of the SMN complex, including SMN [163]. However, the mechanism by which 
SMN promotes the formation of the E complex remains unknown. SMN may affect splicing 
of specific exons by interacting with other splicing factors. Supporting this argument, SMN-
interacting proteins hnRNP U, hnRNP R and FUS were also detected in the E complex 
assembled on MINX [163]. RNA helicases modulate pre-mRNA splicing by unwinding 
RNA structures of pre-mRNAs [164]. Several structural elements have been implicated in 
splicing regulation of SMN as well as other genes [165–171]. In vivo selection of the entire 
exon also supports the role of RNA structure in regulation of SMN exon 7 splicing 
[172,173]. In addition, different types of antisense oligonucleotides annealing to various 
positions within SMN2 pre-mRNA have been shown to promote exon 7 inclusion [174–
183]. The stimulatory effects of these antisense oligonucleotides could be due at least in part 
to perturbations in the local RNA structures. Considering SMN associates with RNA 
helicases, including Gemin3, DDX1, DDX3 and DDX5 [92,96], it is likely that SMN 
modulates its own splicing as well as splicing of other transcripts through helicase 
interactions. Splicing is coupled to transcription and several splicing factors are recruited 
during this process [184,185]. SMN may indirectly affect transcription-coupled splicing 
regulation through its interacting partners, such as FUS and helicases that associate with pol 
II [186]. Since SMN controls pausing at the transcription termination site [90], it may also 
modulate splicing of last introns by recruiting splicing factors during transcription 
termination.
3.6. Transcription
Transcription is a multistep process consisting of initiation, elongation and termination. The 
role of SMN in one or more of these steps could be envisioned based on the finding that 
SMN directly interacts with the CTD of pol II [187]. Independent of pol II interaction, SMN 
also binds to transcription factors and chromatin remodeling complexes [78,98,188]. For 
example, SMN interacts with papillomavirus-encoded transcription factor E2 and enhances 
E2-dependent transcriptional activation [188]. SMN also binds to p53, a transcription factor 
with distinct nuclear localization, DNA-binding and transactivation domains [78]. 
Interestingly, SMN-p53 complex localizes to CBs, which are maintained by WRAP53, an 
SMN-interacting protein generated from the antisense transcript of p53 gene [78,119]. SMN 
binding to E2 and p53 suggests its role in transcription initiation. Supporting its participation 
in chromatin-associated transcription regulation, SMN interacts with SIN3A, a transcription 
co-repressor [98]. SIN3A serves as a master scaffold for histone deacetylases (HDACs) and 
other proteins that modulate chromatin structure and transcription [189]. Transcription 
elongation requires directionality that is decided by the prompt interaction of U1 snRNP 
with the nascent transcript while it is still attached to transcribing pol II [190]. Therefore, 
SMN may also affect transcription elongation indirectly by controlling the rate of biogenesis 
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of U1 snRNP that happens to be the most abundant snRNP in the nucleus. Further, pol II 
creates R-loops in transcription termination regions; these R-loops must be resolved for the 
nascent transcripts to be released from the DNA template. Supporting the role of SMN in 
transcription termination, SMN interacts with Senataxin, a putative DNA/RNA helicase, 
which is involved in the resolution of R-loops [191]. More recently, a role for SMN in 
resolution of R-loops and transcription termination has been established through its direct 
interaction with the symmetrically dimethylated residues of the CTD of pol II [90].
3.7. RNA trafficking
SMN harbors a nucleic acid-binding domain and has preference for homopolymeric G 
residues in vitro [73,74]. An early study suggested the role of SMN in trafficking of β-Actin 
mRNAs in neuronal processes and growth cones [40]. SMN assembled on β-Actin mRNA 
was shown to also interact with hnRNP R, an RNA-binding protein [40]. Other RNA-
binding proteins implicated in mRNA trafficking in motor neurons, such as FMRP, HuD, 
Insulin-Like Growth Factor mRNA-Binding Protein 1 (IMP1), KH-Type Splicing 
Regulatory Protein (KSRP) and hnRNP Q, have been shown to interact with SMN as well 
[87,124–129]. HuD, a member of the Hu family of proteins, is expressed only in neuronal 
cells; it interacts with a wide variety of RNA sequence motifs [192,193]. HuD and IMP1, the 
mammalian homolog of Zip-Code Binding Protein 1 (ZBP1), have been shown to interact 
with overlapping motifs within the 3′UTR of the β-Actin mRNA [193]. While HuD shows 
some preference for U-rich sequence, ZBP1 binds to the ACACCC motif in the structured 
region [193]. Candidate Plasticity-Related Gene 15 (cpg15) mRNA is another target of HuD. 
It has been proposed that SMN facilitates trafficking of HuD-bound cpg15 mRNA to the 
axonic terminals for local translation [127]. More recently, the SMN/HuD/IMP1 complex 
has been implicated in the transport of Growth-Associated Protein 43 (Gap43) in motor 
neurons [130]. Consistently, overexpression of HuD and IMP was found to rescue the axon 
outgrowth defects in cultured primary motor neurons derived from a severe mouse model of 
SMA [130].
Based on the broad sequence specificity of RNA-binding proteins that interact with SMN, 
SMN may be involved in trafficking of a large number of mRNAs in motor neurons. Indeed, 
a transcriptome-wide study employing differentiated NSC-34 motor-neuron-like cells 
identified more than 200 mRNAs, including Smn, as potential targets of SMN [128]. The 
SMN-interacting protein hnRNP Q was found to be one of the major components of the 
SMN complex associated with these mRNAs. However, the presence of other RNA-binding 
proteins, including HuD, IMP1 and KSRP was not verified. Of note, HuR, a widely 
expressed member of the Hu family of proteins, has been shown to stabilize SMN mRNA by 
interacting with its 3′UTR [194]. However, it remains to be seen if the interaction of HuR 
with the 3′UTR of SMN mRNA is modulated by SMN levels and is critical for the 
intracellular trafficking of SMN mRNA.
3.8. Biogenesis of the Signal Recognition Particle
The signal recognition particle (SRP) is a ubiquitously expressed cytosolic RNP complex 
involved in the localization of specific proteins [195,196]. In particular, SRP interacts with 
the newly synthesized hydrophobic N-terminus of proteins that serves as the signal for the 
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transport of these proteins to the endoplasmic reticulum. SRP is comprised of six proteins 
(SRP9, 14, 19, 54, 68, and 72) and a single RNA molecule, 7S RNA [195,196]. The 
secondary structure of 7S RNA can be divided into three distinct folds in which a large S 
domain and a small Alu domain flank the central helix. Supporting the role of SMN in SRP 
biogenesis, the purified SMN complex was found to interact with 7S RNA in vitro [123]. It 
was further shown that Gemin5 directly binds the S-domain and that the SMN complex is 
required for the assembly of the SRP54 protein onto 7S RNA [123]. In addition, the level of 
7S RNA was significantly reduced in the spinal cord of SMA mice, indicating a requirement 
for high levels of SMN for proper expression of functional SRPs [123].
3.9. Translation
SMN has been implicated in translation regulation of Protein Arginine Methyltransferase 4 
(PRMT4), also known as Coactivator Associated Arginine Methyltransferase 1 (CARM1) 
[121]. CARM1 is a multifunctional protein that affects transcription, splicing and autophagy 
[122,197–199]. Downregulation of SMN increases the level of CARM1 [122]. Consistently, 
CARM1 is upregulated in tissues from SMA mouse models as well as in SMA type I patient 
cells [121]. Increased expression of CARM1 has been shown to cause an aberrant increase in 
inclusion of exon 2 of the Ubiquitin-Specific Protease-Like 1 (USPL1) gene that codes for a 
SUMO isopeptidase [122]. The exon 2-containing transcript of USPL1 is also upregulated in 
mouse models of SMA as well as in SMA type I patient cells [122,141,142,200]. These 
findings support a point of view that the aberrant splicing of USPL1 exon 2 in SMA is the 
consequence of upregulation of CARM1. CARM1 interacts with UPF1, a key component of 
the NMD pathway, and affects the fate of a subset of NMD targets [122]. However, NMD 
has been ruled out as a possible mechanism by which exon 2-containing transcripts of 
USPL1 are enriched in SMA [122]. Interestingly, inclusion of USPL1 exon 2 was found to 
be more pronounced in muscle than in spinal cord of SMA mice [141]. It is not known if the 
tissue-specific difference in exon 2-containing transcripts of USPL1 is due to a 
corresponding difference in the CARM1 levels. SMN may also have an indirect role in 
translation repression through the RNA interference pathway, since several microRNAs, 
including miR-9, miR-183, miR-206, miR-132 and miR-431 are aberrantly expressed in 
SMA [201–205]. Some of these microRNAs have been suggested to be potential targets for 
SMA therapy [204,205].
3.10. Selenoprotein synthesis
Humans code for 25 selenoproteins that incorporate selenocysteine (Sec), the 21st naturally 
occurring amino acid, into their primary structure [206]. Incorporation of Sec into 
selenoproteins occurs due to recoding of a stop codon, UGA, when a Sec insertion sequence 
(SECIS) is present downstream [206,207]. SECIS-Binding Protein 2 (SBP2), Sec-Specific 
Translation Elongation Factor (EFsec) and tRNAsec play an important role in Sec 
incorporation into selenoproteins [206]. Recently, mRNAs of a subgroup of selenoproteins 
were also shown to acquire a TMG cap structure through a TGS1-catalyzed reaction in the 
cytosol [100]. The results of this study revealed a RNA-independent interaction among 
SMN, SBP2 and TGS1 [100]. Generally, the TMG cap is associated with nuclear retention. 
However, selenoprotein mRNAs that included a TMG cap were found to be retained in the 
cytosol and were actively translated [100]. These findings point to a novel mechanism by 
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which SMN regulates initiation of translation of a subset of selenoprotein mRNAs. 
Interestingly, mRNA of selenoprotein SepW1 colocalizes with SMN-associated RNP 
complexes in the neurites of the mouse motor-neuron-like NSC-34 cells [128]. These 
observations support a specific role of SMN in trafficking and translation of SepW1 mRNA 
in motor neurons. Several selenoproteins possess antioxidant functions that appear to be 
compromised in a number of diseases [207]. However, the consequences of low SMN levels 
on the synthesis of various selenoproteins in different tissues have not yet been assessed. 
Human SBP2 generates multiple alternatively spliced transcripts under normal and oxidative 
stress conditions [49,208,209]. Future studies will determine if various SBP2 isoforms 
interact with the SMN-TGS1 complex differently with the implications for the trafficking 
and/or translation of specific selenoprotein mRNAs.
3.11. Stress Granule (SG) Formation
SGs are dynamic cytosolic storage hubs for mRNAs, translation initiation of which are 
stalled during stress [210]. SGs share several features with processing bodies (PBs) that are 
cytosolic triage centers of mRNAs [211]. The distinguishing characteristics of SGs are the 
presence of the translation initiation machinery, whereas PBs are defined by the presence of 
the mRNA decay machinery. The repertoire of factors present within SGs is large, varied 
and includes RNA-binding proteins, metabolic enzymes, signaling factors, mRNAs and 
microRNAs [210,211]. SG formation is dysregulated in various pathological conditions, 
including cancer and neurodegeneration [211–213]. SMN localizes to SGs and SMN 
deficiency reduces the ability of cells to form SGs leading to the cell sensitization to stress 
[46,120]. Isolated SMN domains coded by exons 2A+2B or exons 4–7 are able to form 
small SGs [120]. However, the Tudor domain coded by exon 3 along with adjacent domains 
coded by exons 4–7 appear to be essential for the formation of large SGs [120]. Consistent 
with these results, FMRP that interacts with SMN through the Tudor domain has been 
identified as a component of SGs [214]. The fact that the nucleic-acid-binding domain coded 
by exon 2B of SMN is sufficient to form small SGs supports that SMN might transport 
mRNAs to SGs. Cellular levels of SMN are governed by TIA1 and several other factors that 
regulate SMN exon 7 splicing [215]. Similar to SMN, TIA1 is also a component of SGs 
[211]. Sequestration of TIA1 in SGs is likely to reduce its nuclear availability and 
consequently induce skipping of SMN2 exon 7. Future studies will determine if the 
formation of SGs is a mechanism by which SMN senses its own levels so that appropriate 
amount of SMN could be generated and delivered to various subcellular compartments.
4. DNA recombination and repair
Eukaryotic cells employ homologous DNA recombination to effectively repair DNA in 
diploid cells as well as to exchange genetic material between homologous chromosomes 
during meiosis [216–218]. Among the factors involved in homologous recombination, 
RAD51, a eukaryotic recombinase, plays an essential role [219]. In particular, RAD51 forms 
a filament on the single-stranded DNA. The formation of the RAD51 filament is essential 
for the homology search and strand exchange steps of the homologous recombination [219]. 
The homologous pairing and the strand exchange mediated by RAD51 could be 
recapitulated in vitro [220]. Supporting a direct role of SMN in homologous recombination, 
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RAD51 has been shown to interact with GEMIN2 and the SMN-GEMIN2 complex 
[221,222]. It has also been demonstrated that the interaction of RAD51 with the SMN-
GEMIN2 complex enhances the RAD51-mediated homologous pairing and strand exchange 
reaction in vitro (Fig. 4) [221,222]. These findings gain additional significance in light of 
reports supporting a relationship between DNA repair and R-loop-mediated genome stability 
[223]. Since SMN is involved in resolution of R-loop [90], it is possible that the positioning 
of SMN at the R-loop facilitates DNA repair.
In addition, SMN is recruited through an interaction with histone H3 to centromeres in the 
presence of DNA damage and it participates in the induced Centromeric Damage Response 
(iCDR) [89]. SMN also plays an indirect role in DNA damage response due to a dependence 
of histone H2AX expression on SMN levels [117]. Further, DNA damage is repaired during 
transcription elongation through a process called transcription-coupled repair (TCR) [224]. 
Given the interaction of SMN with pol II [90], it is likely that SMN modulates the process of 
TCR. Consistent with the role of SMN in DNA repair, DNA damage has been reported as 
one of the early symptoms in the skeletal muscles of a mouse model of SMA [225]; this 
finding suggests a direct involvement of SMN in DNA repair. DNA damage was also 
recorded as one of the characteristic features of the testicular cells in another mouse model 
of SMA [57].
5. Signal transduction
5.1. Signaling regulating the actin cytoskeleton
Neurites and growth cones are formed by Actin-rich cytoskeletal structures that undergo 
dynamic rearrangements in response to external and internal growth cues [226]. Given the 
localization of SMN to neurites and growth cones [41,227], efforts have been made to 
determine whether and how SMN may regulate rearrangements of these dynamic structures. 
SMN binds to Profilin2a, a neuron-specific Actin-binding protein, via a conserved proline-
rich sequence coded by exon 5 (Fig. 1) [93,228]. SMN knockdown in PC12 cells reduces 
neurite outgrowth and leads to Profilin2a accumulation [229]. Rho-Associated Kinase 
(ROCK) regulates Profilin2a through phosphorylation (Fig. 5A) [230]. In PC12 cells with 
SMN knockdown, Profilin2a is hyperphosphorylated, while other downstream ROCK 
targets, including Myosin Light Chain Phosphatase (MLCP) and Cofilin, are 
hypophosphorylated (Fig. 5A) [228]. Abnormal phosphorylation of these proteins would 
interfere with the required actin cytoskeletal changes necessary for neurite outgrowth. 
Together, these findings link SMN to the RhoA/ROCK pathway. Specifically, SMN and 
ROCK may compete with one another for access to Profilin2a as a mechanism to regulate 
neurite outgrowth [228]. Dysregulation of this pathway could play a role in SMA pathology, 
since it leads to a pronounced effect on neuron integrity and neurodegeneration. Indeed, 
treating an intermediate SMA mouse model (Smn2B/−) with the ROCK inhibitors Y-27632 
or fasudil increases animal survival, although neither compound prevents motor neuron 
death and only Y-27632 partially ameliorates defects in neuromuscular junction (NMJ) 
maturation [233,234].
The Actin-binding protein known as Plastin3 adds another dimension to the role of SMN in 
regulation of the actin cytoskeleton. Plastin3 regulates cytoskeletal dynamics through 
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various mechanisms, including bundling of Actin filaments [235,236]. Interestingly, Plastin3 
is a potential genetic modifier for SMA, since asymptomatic compared to symptomatic 
siblings with SMN1 deletion express higher Plastin3 in lymphoblasts, but not fibroblasts 
[15]. Further, induced pluripotent stem cells from an asymptomatic individual differentiated 
into motor neurons express high Plastin3; this finding indicates that Plastin3 plays a 
protective role in motor neurons and specifically in growth cones [237]. SMN, Plastin3 and 
Actin associate in large protein complexes and Plastin3 overexpression could correct neurite 
outgrowth defects observed in the context of low SMN [15]. In the intermediate Smn2B/− 
mouse model, a decrease in Plastin3 levels occurs concomitantly with an increase in the 
Profilin2a level prior to the onset of symptoms [238]. This finding suggests that deregulation 
of actin dynamics precedes and is likely the mediator of motor neuron degeneration. Animal 
studies have produced ostensibly inconsistent results as to the benefit of Plastin3 
upregulation in the context of low SMN. For example, overexpression of Plastin3 is unable 
to improve survival of severe SMA mice (Taiwanese and Δ7 models), although there is some 
benefit to NMJ formation and function [239,240]. However, when Plastin3 is overexpressed 
in the context of an intermediate SMA mouse model, there is marked improvement in 
lifespan, motor function and NMJ architecture and function [241]. Collectively, these data 
indicate that SMN plays an important and complicated role in regulating the actin 
cytoskeleton.
5.2. Signaling pathways implicated in neurodegeneration
Since degeneration of spinal cord α-motor neurons is a hallmark of SMA, studies have 
examined the potential role of reduced SMN on pathways implicated in neurodegeneration. 
One study tested activation of various Mitogen-Activated Protein Kinases (MAPKs) in 
human SMA and control spinal cord in an attempt to identify pathways that may contribute 
to neurodegeneration [231]. This screening identified activation and increased activity of c-
Jun NH2-Terminal Kinases (JNKs). Consistently, low SMN results in the JNK3 activation 
that contributed to the motor neuron death (Fig. 5B) [231]. While knockout of Jnk3 in the 
context of the Δ7 mouse improves the phenotype, this improvement is not due to an increase 
in SMN protein [231]. Thus, SMN appears to act through upstream regulators of JNK3. 
SMN is also involved in ubiquitin homeostasis, since Ubiquitin-Like Modifying Activator 1 
(Uba1) is markedly reduced in the spinal cord and the gastrocnemius muscle of severe SMA 
mice [232]. Consistently, restoration of UBA1 has been recently shown to ameliorate disease 
pathology in zebrafish and mouse models of SMA (19). Ubiquitination pathways regulate 
axonal and synaptic stability as well as the stability of the SMN protein [8,19,242–244]. 
Uba1 and SMN physically interact in the neuronal cytosol, and reduction of SMN 
dysregulates Uba1 splicing, perhaps leading to the reduction of Uba1 protein [232]. Reduced 
Uba1 would perturb ubiquitin homeostasis and this disturbance could contribute to 
neurodegeneration (Fig. 5C). Interestingly, dysregulation of Uba1 is accompanied by the 
accumulation of β-Catenin, a normal substrate for degradation by ubiquitination. This effect 
appears to be tissue-specific as an increase in β-Catenin occurs only in the spinal cord but 
not in the heart and the liver [232]. While β-Catenin signaling has not been linked to 
neurodegeneration, decreased β-Catenin degradation could cause its increased translocation 
to the nucleus, abnormal gene transcription and subsequent neuronal instability [232]. 
Studies in D. melanogaster implicate the role of SMN in the regulation of the Fibroblast 
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Growth Factor (FGF) signaling pathway that controls the formation of NMJs [245]. 
However, the regulatory role of SMN on FGF signaling in mammalian systems has yet to be 
investigated. Taken together, these findings indicate that low SMN perturbs numerous 
signaling pathways that could contribute to neurodegeneration.
6. Intracellular trafficking, endocytosis and autophagy
6.1. Intracellular trafficking
Several studies suggest that SMN mediates neurite outgrowth through participation in 
intracellular trafficking of mRNA [39,40,128]. SMN localizes in granules found throughout 
neurites and in growth cones of cultured spinal cord motor neurons [38]. SMN, along with 
hnRNP R, contributes to localization of β-Actin mRNA to growth cones, and SMN 
deficiency impairs neurite outgrowth and β-Actin mRNA localization in growth cones [40]. 
More recent studies investigated the mechanism by which SMN localizes to growth cones to 
exert its influence [43]. COPI is a protein complex that mediates vesicular transport between 
the cis end of the Golgi apparatus and the endoplasmic reticulum [246]. This complex also 
appears to function in intracellular trafficking in neurites [43]. In axonal growth cones, SMN 
directly interacts with the COPI coatomer protein complex, specifically the α-COP protein, 
along with Gemin2 and Gemin3 proteins and β-Actin mRNA [43]. Depletion of α-COP in 
SH-SY5Y cells decreases neurite outgrowth and disrupts SMN localization at the 
lamellipodium, an Actin-rich dynamic structure [43]. α-COP interacts with SMN through 
dilysine motifs coded by exon 2b [247], and this interaction is critical for normal neurite 
outgrowth in PC12 cells and for motor axon development in zebrafish [248]. Further, 
knockdown of α-COP in NSC34 cells results in the accumulation of Smn granules in the 
Golgi apparatus [44]. Taken together, these results suggest that neurite outgrowth requires 
SMN localization to the growth cones.
When localized to growth cones, SMN could modulate neurite outgrowth through actin 
cytoskeleton rearrangement. In fibroblasts, SMN is recruited to the actin cortex to structures 
that mediate remodeling of the cytoskeleton [249]. SMN interacts with Caveolin-1, a 
component of caveolae in the plasma membrane, to form a translational platform that 
sequesters inactive ribosomes. Under appropriate cues, SMN releases these inactive 
ribosomes to actively translating polyribosome machinery to quickly alter the actin 
cytoskeleton. SMN reduction depletes the plasma membrane of inactive ribosomes and 
attenuates its dynamic remodeling [249]. Once localized to growth cones, SMN could 
stabilize these translational platforms to allow for rapid translation of β-Actin to allow for 
dynamic changes in the cytoskeleton. This potential role of SMN is attractive, since SMN 
mediates localization of β-Actin to growth cones [40]. Further research will be required to 
ascertain whether this mechanism occurs in neurons.
6.2. Endocytosis
Endocytosis is the de novo production of internal membranes from the plasma membrane 
lipid bilayer. This process internalizes integral membrane proteins, lipids and extracellular 
content [250]. Since endocytosis depends on actin cytoskeleton remodeling [251], it is not 
surprising that SMN is involved in endocytosis. In C. elegans, smn-1 depletion impairs 
Singh et al. Page 14
Biochim Biophys Acta. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
synaptic transmission by interfering with the endocytic process of synaptic vesicle recycling 
[252]. Further, smn-1 depletion causes widespread endosomal deficits, including abnormal 
localization of endosomal proteins, defects in endosomal trafficking in neuronal and non-
neuronal tissue and impaired JC polyomavirus (JCPyV) infection, a process mediated by 
Clathrin-coated endocytosis [252]. In severe SMA mice (Taiwanese model), endocytosis in 
transversus abdominis muscle was found to be disturbed when these muscles were subjected 
to electrical stimulation [241]. Interestingly, overexpression of Plastin3 restores endocytosis; 
this finding indicates the potential phenotype-modifying capability of this gene [241]. 
Plastin3 also interacts with CORO1C, an Actin-binding protein implicated in endocytosis 
[253]; together these proteins could rescue endocytosis defects in SMN depleted cells [241]. 
As stated previously, SMN interacts with Caveolin-1, a major component of caveolae, and 
these structures can mediate endocytosis through actin cytoskeleton remodeling [250,254]. 
However, the exact mechanism by which SMN modulates endocytosis remains unknown.
6.3. Autophagy
Autophagy is a highly-regulated process important for normal cell growth and 
differentiation. In autophagy, cytosolic proteins and organelles become enclosed in double-
membrane vesicles and are degraded through fusion with the lysosome [255]. Autophagy is 
deregulated in several neurodegenerative diseases, including ALS [256,257]. This 
deregulation could at least partially explain motor neuron death in SMA. Autophagy is 
mediated by the multifunctional signaling hub protein p62/Sequestosome-1, which 
recognizes both ubiquitinated proteins that are destined for degradation and the Light Chain 
3 (LC3) protein in the membrane of the forming autophagosomes [255]. Smn knockdown in 
cultured mouse embryonic spinal cord motor neurons leads to accumulation of LC3-II, an 
indication of autophagosome formation, in the soma and neurites [258]. This increase was 
proposed to be attributed to an induction of autophagosome production, but not altered 
autophagic flux (e.g. autophagic degradation activity). However, in NSC34 cells with Smn 
knockdown, autophagic flux is compromised; specifically, the autophagosome fails to fuse 
with the lysosome [259]. This failure could be related to compromised intracellular 
trafficking correlated with an increase in the microtubule destabilizing protein Stathmin 
[260]. Of note, upregulated Stathmin reduces the amount of polymerized Tubulin and this 
disruption could compromise intracellular trafficking and interfere with fusion of the 
autophagosome and lysosome [259]. In severe SMA mice (Taiwanese model), there is an 
increase in LC3-II and p62 protein in the spinal cord as well as an increase in LC3-positive 
puncta during embryonic and postnatal time points [261]. Taken together, these findings 
suggest that SMN reduction deregulates autophagy within motor neurons, although it is 
unclear to which extent this deregulation contributes to motor neuron death.
7. System-wide role of SMN: Lessons learned from the animal models of 
SMA
Since the discovery that SMN1 is the causative gene for SMA, much effort has gone into 
developing animal models of the disease. These animal models serve to not only understand 
the impact of low SMN on the development and function of tissues, but to allow for the 
testing of potential treatments for SMA. A complete description of animal models of SMA is 
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beyond the scope of this review. Here we briefly touch upon certain observations with 
implications to the specific functions of SMN. Several species serve as models for SMA, 
from the invertebrate nematode (C. elegans) and fruit fly (D. melanogaster) to the vertebrate 
zebrafish (Danio rerio) and mouse (Mus musculus) [262]. C. elegans and D. melanogaster 
are convenient models to examine the impact of low SMN because the endogenous smn is 
easy to manipulate, replication time of these animals is short and their development is well 
characterized [262]. Consistent with the critical role of the SMN N-terminus that interacts 
with Gemin2, p53 and nucleic acids (Fig. 1), a point mutation (D44V) at the N-terminus led 
to the impairment of the late-larval development and caused progressive motor function 
(thrashing) defects in Caenorhabditis elegans [263]. In case of Drosophila, a SMA-patient-
associated point mutation (G275S) in the conserved YG-box showed NMJ defects [264]. 
Other point mutations in YG-box of SMN showed a wide variety of phenotypes in 
Drosophila [265]. Interestingly, the snRNP biogenesis function was found to be not a major 
contributor to the SMA phenotype in Drosophila [266]. Supporting the neuron-specific 
function of SMN, knockdown of SMN in zebrafish triggers defects in motor neuron 
outgrowth and pathfinding [267]. Validating the critical role of SMN C-terminus in 
conferring protein stability (7–9), truncations or point mutations in C-terminus cause NMJ 
defects and reduces life expectancy in zebrafish [268]. In concurrence with the findings in 
Drosophila supporting a lack of correlation between snRNP biogenesis and SMA disease 
pathology [266], experiments in zebrafish suggested that snRNP assembly function of SMN 
is not critical for rescuing the motor exon defects [101]. Overall, studies in Drosophila and 
zebrafish underscore the utility of these models in determining the impact of specific 
function of SMN in disease progression.
Mouse models of SMA offer a rich source to examine multi-organ effects of low SMN and 
to test various therapeutic strategies for SMA. Mice carry the gene Smn, which similar to 
SMN1 predominantly includes exon 7, and as mentioned before, knockout of Smn is 
embryonic lethal [11]. Transgenic mouse models of SMA are usually generated by knocking 
out of the Smn gene coupled with the addition of various copy numbers of the SMN2 
transgene [10,12,269]. These models generally exhibit a severe phenotype with markedly 
reduced lifespan and are useful in evaluating early postnatal development of organ systems. 
A significant body of work has examined the impact of low SMN on the nervous system, 
especially the critical role of SMN in the maturation and function of the NMJ [45,270–272]. 
Collectively, these studies reveal that reduced SMN leads to the accumulation of 
Neurofilament protein at motor nerve plates, reduced arborization, abnormal synaptic vesicle 
localization, immature plaque-like NMJs and impaired neurotransmission. High SMN is 
required for the normal maturation of the NMJ; mice exhibit an insensitivity to reduced 
SMN beginning at P17, an age that correlates with maturation of NMJs [273]. The exact 
mechanism by which SMN influences the maturation of the NMJ remains unclear. Given the 
interaction of SMN with the cytoskeletal (especially actin) system [228], it is tempting to 
speculate that the defects could be caused by perturbed cytoskeleton regulation. In reality, 
the role of SMN in NMJ development and maturation likely involves multiple steps. In the 
Δ7 mouse, the dysregulation of synaptogenesis genes precedes the overt motor neuron 
pathology [274]. Notable changes include alternative splicing of Agrin, a protein crucial for 
NMJ maintenance, upregulation of synaptic pruning factor C1q and downregulation of the 
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transcription factor Etv1/ER81 [274]. The early changes in transcriptome indicate that SMN 
may tightly regulate the motor circuit and its reduction can impair the normal expression of 
relevant factors.
While SMA mouse models illustrate the importance of SMN in the nervous system [275], 
increasing evidence shows that SMN has a pronounced effect on tissues outside of the 
nervous system. SMN reduction affects the development and function of the cardiovascular 
system [276–278], lungs [278,279], bone [280], intestine [278,281,282], liver [283,284], 
pancreas [285], spleen [286] and testis [57]. Although the exact mechanism by which SMN 
influences the development and function of these organs is a matter of future investigation, it 
is clear that in addition to the nervous system the effective treatments for SMA will need to 
address peripheral organ defects as well. Interestingly, a recent study captured significant 
differences in life expectancy, muscle and NMJ pathology upon change in genetic 
background of a mouse model of SMA [287]. Findings of this study underscore why SMA 
patients display a much wider spectrum despite in many cases carrying the identical 
mutations. These findings also emphasize the need to understand the system-wide network 
of SMN interactions that are likely to vary in cells originating from different individuals.
8. Conclusions
Since the first report in 1995 that SMN1 mutations cause SMA, tremendous progress has 
been made toward our understanding of SMN functions. SMN is a housekeeping protein that 
performs essential functions in both the cytosol and the nucleus. The multiplicity of SMN 
functions is rooted in the diversity of the SMN-interacting partners that associate with 
distinct SMN domains, including the N-terminal lysine-rich domain, the central Tudor and 
proline-rich domains as well as the C-terminal YG box. SMN modulates almost every aspect 
of RNA metabolism, including transcription, splicing, biogenesis of snRNPs, snoRNPs, 
telomerase, the 3′-end processing of histone mRNAs, translation, selenoprotein synthesis, 
stress granule formation and mRNA transport. A vast majority of SMN functions require 
interaction of the Tudor domain with a symmetrically dimethylated protein [79–81]. In 
several instances, SMN executes its functions through the formation of the multi-component 
RNP complexes of varied compositions. However, the specific role of SMN in most of these 
complexes remains unknown. SMN harbors a distinct nucleic-acid-binding domain that 
shows preference for G-rich sequences in vitro [73]. SMN also interacts with RNA-binding 
proteins that are involved in trafficking of mRNAs within motor neurons. Future studies will 
determine if a direct interaction between SMN and RNAs is the driving force behind the 
formation of various RNP complexes.
Independent of its role in RNA metabolism, SMN regulates other functions, including but 
not limited to DNA repair, cell signaling, endocytosis, autophagy and the neuronal 
cytoskeleton. Early death of motor neurons in severe SMA triggers a series of events 
common to several neurodegenerative diseases. It is likely that low levels of SMN in motor 
neurons simultaneously impact multiple functions. Peripheral defects in mild SMA point to 
the intrinsic need for SMN in all tissues. Studies on disease-modifying factors of SMA 
suggest that the impact of low levels of SMN could be partially mitigated but not fully 
compensated. This suggestion is consistent with the involvement of SMN in key cellular 
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processes, which require high precision and fine-tuning. Based on the mislocalization of 
SMN and/or perturbations in SMN-associated functions, the role of SMN has been 
implicated in inclusion-body myositis and ALS [52,53]. In the case of osteoarthritis, SMN is 
expressed at an aberrantly high level in cartilage [54]. On the other hand, low SMN 
expression has been recently linked to testicular defects and male infertility [57]. These 
results support that both aberrantly low and high SMN expression could result in 
pathological conditions. The number of SMN-associated pathologies is likely to grow based 
on the diverse nature of interactions forged by SMN. Considering its involvement in 
upstream events such as transcription, splicing, mRNA trafficking and translation, SMN has 
the potential to regulate its own expression. Our understanding of SMN functions will 
continue to improve as we acquire more knowledge of the mechanism of various cellular 
processes. With a better understanding of SMN functions, we will uncover novel disease 
mechanisms, which will bring us closer to effective and targeted therapies for SMA and 
other related diseases.
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Figure 1. Structure of SMN protein and SMN transcripts
(A) Diagrammatic representation of the SMN protein. The numbers in the colored box 
indicate the exon. Domains are indicated above the boxes and proteins shown to interact 
with SMN are shown below. See text for further details about proteins. (B) Comparative 
modeling of the full-length SMN protein utilized multiple structure templates for the 
Gemin2 binding domain (blue) [20,21], the Tudor domain (green) [22–24] and the YG Box 
domain (orange) [25]. Model calculations with RosettaCM included the structure templates 
for the domains and fragment libraries derived from sequence-based searches of the Protein 
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Data Bank for modeling all other regions [26]. The SMN protein diagram shows the 
structural domains in color overlaid on a map of the labeled exons with the number of the 
last amino acid residue in each exon indicated above. The structural domains and amino 
ranges are indicated below the diagram. The full-length SMN protein model is shown as a 
cartoon representation with a rainbow color scheme from blue N-terminus to red C-terminus 
(labeled N and C, respectively) [27]. The structured domains are indicated with the PDB 
codes of the comparative modeling templates listed below each name. The unstructured 
regions highlighted include the lysine-rich region, and the Profilin2a binding region with the 
conserved proline-rich sequence indicated below the label. Selected amino acid side chains 
are shown as stick representations with blue for lysine amino groups and red for tyrosine 
hydroxyl groups. The conserved residues of the YG Box motif are indicated with the Cα 
atoms of the glycine residues shown a van der Waals spheres. (C) Diagrammatic 
representation of transcripts generated from SMN. The name of each transcript is indicated 
to the left. Start and stop codons are indicated for each transcript, the exon number is 
indicated above the colored boxes and the number of amino acids coded by each exon is 
indicated in the boxes. The EMLA degron [9] that renders SMNΔ7 unstable is indicated. 
Abbreviation: UTR, untranslated.
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Figure 2. Alignment of SMN protein from various animal species
Exon numbers correspond to human SMN exons. Sequences were aligned with the ClustalW 
algorithm using MacVector software. The name of each species is indicated to the left of the 
sequence and accession numbers are indicated at the end of the sequence. Bold letters 
highlighted in grey indicate consensus amino acids. The highly conserved Gemin2 
interaction, Tudor domain, polyproline-rich domain YG Box are denoted. Adapted from 
[50].
Singh et al. Page 37
Biochim Biophys Acta. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Proposed RNA metabolism roles of SMN
SMN is pictured at the center and is represented in all cases by a blue circle. All RNAs are 
represented by red line drawings, all DNA in black, and all proteins as colored ovals or 
circles. Starting from the top left, in clockwise order, the functions are as follows. (A) 
Transcription termination: SMN interacts with symmetrically dimethylated arginines in the 
C-terminal domain CTD of polymerase II, and is proposed to assist in targeting the 
Senataxin helicase to R-loops [90]. (B) U7 snRNP assembly: The SMN complex loads the 
Sm/Lsm ring onto U7 snRNA [116,117]. Afterwards, the mature snRNP functions in 3′ end 
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processing of histone mRNAs [117]. (C) SRP biogenesis: the SMN complex is required for 
proper interaction between SRP54 and the 7S RNA, which is required for targeting of 
nascent polypeptides to the endoplasmic reticulum [123]. SRP54 is pictured as a purple oval. 
(D) Spliceosomal snRNP assembly: SMN functions along with the other components of the 
SMN complex [20,72,108–115] in assembly of the heptameric Sm ring onto snRNA [109]. 
After assembly, mature snRNPs catalyze pre-mRNA splicing in the nucleus. (E) Telomerase 
biogenesis: Functional telomerase contains an RNA component (TERC) as well as several 
proteins. SMN interacts with telomerase-associated proteins GAR1, TERT, Dyskerin, and 
WRAP53, and is proposed to function in targeting telomerase to Cajal bodies (CBs) 
[82,107,119]. (F) Selenoprotein translation: SBP2 causes incorporation of selenocysteine 
(Sec) in the place of a stop codon. In addition, many selenoprotein mRNA 5′ ends are 
hypermethylated by TGS1 [100]. SMN interacts with both SBP2 and TGS1 [100]. (G) 
snoRNP biogenesis: H/ACA and C/D class snoRNPs consist of RNA and a characteristic set 
of protein cofactors for each class. SMN interacts with Fibrillarin, a component of C/D class 
snoRNPs [118], and GAR1 and Dyskerin within H/ACA class snoRNPs [82,107]. (H) RNA 
trafficking: SMN interacts with a number of RNA binding proteins known to assist in 
targeting of mRNAs to axon terminals [87,124–129], and appears to actively participate in 
the process [40,127–130]. (I) Stress granule formation: SMN is present in stress granules 
(SGs) and low levels of SMN impair the formation of SGs [46,120]. (J) Translation 
regulation: SMN regulates the level of CARM1 protein [121] through a translation-
dependent mechanism proposed to involve a direct interaction between SMN and polysomes 
[122].
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Figure 4. Proposed function of SMN in double-strand break repair
Double-strand DNA break repair is a multi-step process that involves replication of DNA 
from a homologous chromosome. First, one strand from each end is digested by 
exonucleases and the newly generated single-stranded DNA (ssDNA) region is bound by the 
RPA complex. Next, BRCA2 oligomers are recruited to RPA-bound ssDNA and help to 
nucleate RAD51 oligomerization on the ssDNA. RAD51 then continues to oligomerize and 
completely replaces RPA on the ssDNA. RAD51-coated ssDNA then attempts to pair with 
homologous regions of double-stranded DNA (dsDNA). A SMN-Gemin2 fusion protein 
increases the association of RAD51-ssDNA with heterologous dsDNA in vitro [222], and so 
is proposed to function at this stage. Once a homologous region of dsDNA is identified, it is 
invaded by the ssDNA and strand extension takes place. At this stage, there are multiple 
outcomes, depending on whether there is crossover between the homologous chromosomes 
and whether both ends of the break are extended. For brevity’s sake, the simplest outcome, 
synthesis dependent strand annealing, in which a single strand is extended and then re-
anneals with its complementary strand, is portrayed here. For a more detailed overview of 
double-stranded break repair, see Godin et al 2016 [219].
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Figure 5. SMN involvement in signaling pathways
(A) SMN involvement in regulation of actin dynamics. Rho-Associated Kinase (ROCK) 
phosphorylates Lim Kinase (LIMK) which in turn phosphorylates Cofilin (denoted by P in 
yellow circle) to contribute to actin dynamics regulation. SMN can prevent ROCK-mediated 
phosphorylation of Profilin2a (p2a) by interacting and forming a complex with p2a. When 
SMN is reduced, the interaction between p2a and ROCK increases, with a concomitant 
increase in p2a phosphorylation and a decrease in LIMK and Cofilin phosphorylation. 
Consequently, actin dynamics are deregulated and this leads to neurite outgrowth inhibition 
and neurodegeneration [228]. (B) SMN regulates the activation of c-Jun NH2-Terminal 
Kinases 3 (JNK3) by an unknown mechanism. When SMN is reduced, there is an increase in 
phosphorylation and thus activation of JNK3 and a subsequent increase in c-Jun 
phosphorylation. This increased activation can lead to neurodegeneration [231]. (C) SMN 
binds to and can regulate the level of Ubiquitin-Like Modifier Activating Enzyme 1 (UBA1; 
denoted by the dashed arrow). UBA1 can subsequently initiate the ubiquitination pathway 
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that leads to degradation of target proteins. A reduction in UBA1 alters ubiquitin 
homeostasis and may lead to neurodegeneration [232].
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